Skip to main content
UniHealth

Doctor search

Christopher Tsung-Jer Chen, MD

Internal Medicine · Stanford

NPI 1467865527

Medicare standing
Clear
Enrolled, allowed to bill and order, not excluded
Plans that list them
14
3 carriers
Office
1

Offices

1 location · Stanford Health Care · 3,152 clinicians in this group

Looking this up.

Hospitals listed: Stanford Health Care. That is not proof they admit you there this week.

Plans that list them

14 plans · 3 carriers

A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Chen’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.

14 of 14 plans

Plans whose provider directory lists this clinician
Alignment Health BreathEasy (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Clarity (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Harmony (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health Heart & Diabetes (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Heart & Diabetes CalPlus (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Heart & Diabetes Care (HMO C-SNP)Alignment Health PlanListedSep 28, 2026
Alignment Health Heart & Diabetes Choice (HMO C-SNP)Alignment Health PlanListedSep 28, 2026
Alignment Health Honor+ Plan (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health My Choice CalCare (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health Silicon (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health smartHMO (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health the ONE (HMO)Alignment Health PlanListedOct 3, 2026
SCAN Strive (HMO C-SNP)SCAN Health PlanListedOct 3, 2026
DualConnect (HMO D-SNP)Santa Clara Family Health PlanListedSep 1, 2026

California Medical Board record

Licence A169072 · Current

Licensed to practise in California · since 2020 · expires 2028-06-30 · Washington University in St. Louis School of Medicine.

No disciplinary actions, convictions, malpractice judgments or citations in this record.

Checkups this office reported

Medicare did not publish checkup rates for this clinician.

Medicare’s overall office score
76.5 / 100
Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.

Hospitals they work in

1 hospital

These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.

  • Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend it
    Overall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Stanford Health Care

Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.

Every scored measure at Stanford Health Care
Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths5.31 (4.24 to 6.37) · 8,661 casesWorseJul 2022 – Jun 2024
Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits14.1 (12.7 to 15.7) · 2,191 casesWorseJan 2024 – Dec 2024
Postoperative respiratory failure rateComplications and deaths4.08 (1.95 to 6.21) · 5,296 casesBetterJul 2022 – Jun 2024
Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections0.317BetterOct 2024 – Sep 2025
Clostridium Difficile (C.Diff)Infections0.446BetterOct 2024 – Sep 2025
SSI - Colon SurgeryInfections0.241BetterOct 2024 – Sep 2025
Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits0.7 (0.6 to 0.9) · 3,348 casesBetterJan 2024 – Dec 2024
Abdominopelvic accidental puncture or laceration rateComplications and deaths1.06 (0.45 to 1.67) · 5,374 casesNo differentJul 2022 – Jun 2024
CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths0.86 (0.72 to 1)No differentJul 2022 – Jun 2024
Death rate among surgical inpatients with serious treatable complicationsComplications and deaths166.09 (137.88 to 194.3) · 470 casesNo differentJul 2022 – Jun 2024
Death rate for CABG surgery patientsComplications and deaths1.1 · 192 casesNoneJul 2022 – Jun 2025
Death rate for COPD patientsComplications and deaths6.4 · 146 casesNoneJul 2022 – Jun 2025
Death rate for heart attack patientsComplications and deaths9.7 · 253 casesNoneJul 2022 – Jun 2025
Death rate for heart failure patientsComplications and deaths6.3 · 880 casesNoneJul 2022 – Jun 2025
Death rate for pneumonia patientsComplications and deaths10.3 · 935 casesNoneJul 2022 – Jun 2025
Death rate for stroke patientsComplications and deaths8.7 · 501 casesNoneJul 2023 – Jun 2025
Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths2.1 · 7,730 casesNoneJul 2024 – Jun 2025
Iatrogenic pneumothorax rateComplications and deaths0.13 (0 to 0.27) · 20,799 casesNo differentJul 2022 – Jun 2024
In-hospital fall-associated fracture rateComplications and deaths0.28 (0.14 to 0.43) · 23,182 casesNo differentJul 2022 – Jun 2024
Postoperative acute kidney injury requiring dialysis rateComplications and deaths0.94 (0.2 to 1.68) · 5,694 casesNo differentJul 2022 – Jun 2024
Postoperative hemorrhage or hematoma rateComplications and deaths2.36 (1.54 to 3.19) · 7,846 casesNo differentJul 2022 – Jun 2024
Postoperative sepsis rateComplications and deaths5.2 (3.76 to 6.64) · 5,603 casesNo differentJul 2022 – Jun 2024
Postoperative wound dehiscence rateComplications and deaths1.38 (0.23 to 2.53) · 2,211 casesNo differentJul 2022 – Jun 2024
Pressure ulcer rateComplications and deaths0.52 (0.21 to 0.83) · 19,915 casesNo differentJul 2022 – Jun 2024
Rate of complications for hip/knee replacement patientsComplications and deaths3.6 · 416 casesNoneApr 2023 – Mar 2025
Central Line Associated Bloodstream Infection (ICU + select Wards)Infections0.869No differentOct 2024 – Sep 2025
MRSA BacteremiaInfections0.857No differentOct 2024 – Sep 2025
SSI - Abdominal HysterectomyInfections0.368No differentOct 2024 – Sep 2025
Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits16.2 · 247 casesNoneJul 2023 – Jun 2025
Heart failure (HF) 30-Day Readmission RateUnplanned return visits20.5 · 1,021 casesNoneJul 2023 – Jun 2025
Hospital return days for heart attack patientsUnplanned return visits47.8 · 258 casesNoneJul 2022 – Jun 2025
Hospital return days for heart failure patientsUnplanned return visits-1.6 · 990 casesNoneJul 2022 – Jun 2025
Hospital return days for pneumonia patientsUnplanned return visits20.8 · 976 casesNoneJul 2022 – Jun 2025
Pneumonia (PN) 30-Day Readmission RateUnplanned return visits16.5 · 959 casesNoneJul 2023 – Jun 2025
Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits5.2 (4.4 to 6.2) · 2,191 casesNo differentJan 2024 – Dec 2024
Rate of readmission after hip/knee replacementUnplanned return visits5.1 · 425 casesNoneJul 2023 – Jun 2025
Rate of readmission for CABGUnplanned return visits9.6 · 158 casesNoneJul 2023 – Jun 2025
Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits19.6 · 183 casesNoneJul 2023 – Jun 2025
Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits12.7 (10.4 to 15.4) · 4,578 casesNo differentJan 2022 – Dec 2024

What patients said (6,810 patients answered, 25% of those asked)

Patient survey stars by topic at Stanford Health Care
Cleanliness4
Nurse communication4
Doctor communication4
Communication about medicines3
Discharge information4
Overall hospital rating4
Quietness2
Recommend hospital5
Share of patients giving the best answer at Stanford Health Care
Room was "always" clean75%
Nurses "always" communicated well82%
Doctors "always" communicated well81%
Staff "always" explained63%
Yes, staff "did" give patients this information89%
Yes, staff "did" give patients information about help after discharge89%
Doctors "always" explained things so they could understand76%
Doctors "always" listened carefully80%
Doctors "always" treated them with courtesy and respect87%
Patients who gave a rating of "9" or "10" (high)79%
Staff "always" explained new medications76%
Nurses "always" explained things so they could understand77%
Nurses "always" listened carefully79%
Nurses "always" treated them with courtesy and respect88%
"Always" quiet at night53%
"YES", patients would definitely recommend the hospital83%
Staff "always" explained possible side effects50%
Yes, staff "did" give patients information about possible symptoms90%

Original Medicare doctor bills

$82,509

Medicare paid this office $82,509 for 223 people. Most of that is long return visits and Botox.

This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.

Largest Original Medicare bills
Long return visit (40+ min)75$26,048$168
Long return visit (40+ min)38$12,799$129
New patient visit (60+ min)52$10,881$205
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes35$9,474$106
Return visit (30+ min)38$5,948$124
See all 8 services
Every Original Medicare service billed
Long return visit (40+ min)75$26,048$168
Long return visit (40+ min)38$12,799$129
New patient visit (60+ min)52$10,881$205
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes35$9,474$106
Return visit (30+ min)38$5,948$124
Initial hospital care with moderate level of medical decision making at least 75 minutes27$4,973$155
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes15$2,761$71
Hospital discharge day management, more than 30 minutes21$2,204$105

Who their Medicare patients are

223 Original Medicare patients in 2024. Average age 73 · Under 65 11% · 85 and older 7% · Women 48% · Also on Medicaid 29% · Health risk score 2.72. Above the middle of the specialty; the typical internal medicine clinician is at 1.76.

Conditions among them: High blood pressure 71% · Cancer 57% · Diabetes 37% · Chronic kidney disease 31% · Coronary heart disease 30% · Atrial fibrillation 22% · Depression 22% · Heart failure 20% · Dementia 15% · COPD 12% · Stroke 11%.

The office billed $390,273, Medicare allowed $104,670 and paid $82,509; for 618 services of 20 kinds.

Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.

Year by year

Original Medicare by year
2024223618732.72$390,273$82,509
2023170418733.16$245,914$45,804
2022200558732.76$273,298$61,399
2021130512722.49$232,032$57,967
20201217731.96$7,841$1,315

Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.

See the services billed each year

2023: 7 services

Original Medicare services billed in 2023
Long return visit (40+ min)75$21,212$129
New patient visit (60+ min)42$7,014$167
Return visit (30+ min)41$4,771$88
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes21$3,904$72
Initial hospital care with straightforward or low-level medical decision making at least 55 minutes16$2,018$119
Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes18$1,806$45
Hospital discharge day management, more than 30 minutes12$1,285$107

2022: 8 services

Original Medicare services billed in 2022
Long return visit (40+ min)61$27,946$129
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes59$9,393$94
New patient visit (60+ min)37$6,172$167
Return visit (30+ min)27$3,907$91
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes35$3,602$65
Initial hospital care with moderate level of medical decision making at least 75 minutes17$3,078$181
Initial hospital care with straightforward or low-level medical decision making at least 55 minutes23$2,857$124
Hospital discharge day management, more than 30 minutes22$2,178$99

2021: 9 services

Original Medicare services billed in 2021
Long return visit (40+ min)51$26,856$128
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes32$8,596$94
New patient visit (60+ min)29$5,018$173
Initial hospital care with moderate level of medical decision making at least 75 minutes23$4,211$183
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes26$3,958$66
Return visit (30+ min)19$2,956$92
Hospital discharge day management, more than 30 minutes21$2,079$99
Initial hospital care with straightforward or low-level medical decision making at least 55 minutes12$1,519$127
Hospital discharge day management, 30 minutes or less11$739$67

Medicaid work

$2,291 in 2024

Medicaid paid $2,291 for 17 billed services this clinician did in 2024, up to 13 people in a month for one service.

Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.

Largest Medicaid services in 2024
Long return visit (40+ min)17$2,291
Medicaid work by year
202417113$2,291
202330113$2,460
202239115$2,454
202187115$3,786
See the largest Medicaid services in earlier years

2023

Largest Medicaid services in 2023
Long return visit (40+ min)30$2,460

2022

Largest Medicaid services in 2022
Long return visit (40+ min)39$2,454

2021

Largest Medicaid services in 2021
Long return visit (40+ min)87$3,786

Money from drug and device companies

$63 in 2025

Industry payments by year
202522None$63
202411$1,635$1,635
202311None$62
202258None$179
202113None$146
201911$1,006$1,006

Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.

A payment is not proof that care is biased.

Payments by company
GenentechNone$49
1 payment
  • Meals · 2025-02-11 · $49
Karyopharm TherapeuticsXpovio$14
1 payment
  • Meals for Xpovio · 2025-01-28 · $14
See all 2 published payments
Every published payment
GenentechMeals · 2025-02-11None$49
Karyopharm TherapeuticsMeals · 2025-01-28Xpovio$14
See earlier years (2024, 2023, 2022, 2021, 2019)

2024: $1,635

Payments by company in 2024
Janssen Scientific AffairsRybrevant$1,635
1 payment
  • Consulting for Rybrevant · 2024-06-06 · $1,635

2023: $62

Payments by company in 2023
Boehringer Ingelheim PharmaceuticalsNone$62
1 payment
  • Meals · 2023-01-21 · $62

2022: $179

Payments by company in 2022
Janssen BiotechDarzalex$68
3 payments
  • Meals for Darzalex · 2022-07-28 · $32
  • Meals · 2022-04-15 · $17
  • Meals for Erleada · 2022-04-04 · $18
Karyopharm TherapeuticsXpovio$47
2 payments
  • Meals for Xpovio · 2022-10-27 · $24
  • Meals for Xpovio · 2022-06-15 · $23
Pharmacyclics LLC an AbbVieImbruvica$26
1 payment
  • Meals for Imbruvica · 2022-10-08 · $26
AstraZeneca Pharmaceuticals LPNone$23
1 payment
  • Meals · 2022-06-23 · $23
E.R. Squibb & Sons L.L.C.Opdivo$15
1 payment
  • Meals for Opdivo · 2022-02-10 · $15

2021: $146

Payments by company in 2021
PfizerInlyta$146
3 payments
  • Education for Inlyta · 2021-09-30 · $13
  • Education for Inlyta · 2021-05-06 · $124
  • Education for Inlyta · 2021-05-06 · $8

2019: $1,006

Payments by company in 2019
Foundation MedicineFoundationact$1,006
1 payment
  • Consulting for Foundationact · 2019-01-03 · $1,006

Research money

Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.

Research payments by company and study
ADC THERAPEUTICS AMERICA, INC. · Zynlonta · 2025Their institution$377,224
ADC Therapeutics America, Inc. · A Phase 1b, Open-Label, Dose-Escalation and Dose-Expansion Study To Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of Camidanlumab Tesirine (Adct-301) As Monotherapy Or in Combination in Patients With Selected Advanced Solid · 2022Their institution$368,103
Genentech, Inc. · Ph 1a 1b of Accr8 in Solid Tumors · 2025Their institution$182,091
Takeda Pharmaceuticals U.S.A., Inc. · A Phase 1b/2 Study of Tak-981 Plus Pembrolizumab To Evaluate the Safety, Tolerability, and Antitumor Activity of the Combination in Patients With Select Advanced Or Metastatic Solid Tumors · 2024Their institution$167,810
Takeda Pharmaceuticals U.S.A., Inc. · A Phase 1b/2 Study of Tak-981 Plus Pembrolizumab To Evaluate the Safety, Tolerability, and Antitumor Activity of the Combination in Patients With Select Advanced Or Metastatic Solid Tumors · 2022Their institution$142,573
Partner Therapeutics, Inc. · A Study of Zenocutuzumab (Mcla-128) in Patients With Solid Tumors Harboring An Nrg1 Fusion (Enrgy) · 2025Their institution$126,558
ADC Therapeutics America, Inc. · Adct-601-102 · 2024Their institution$97,013
Seagen Inc. · A Phase II, Open Label Study of Tucatinib Combined With Trastuzumab in Patients With Her2+ Metastatic Colorectal Cancer (Mountaineer) · 2023Their institution$85,313
Genentech, Inc. · Ph 1a 1b of Accr8 in Solid Tumors · 2024Their institution$65,670
ADC Therapeutics America, Inc. · Adct-601-102 · 2023Their institution$60,483
Boehringer Ingelheim Pharmaceuticals, Inc. · Brightline-2 Phiia/Iib Brigimadlin Mono in Mdm2 Amp Tumors · 2024Their institution$58,944
Seagen Inc. · A Phase II, Open Label Study of Tucatinib Combined With Trastuzumab in Patients With Her2+ Metastatic Colorectal Cancer (Mountaineer) · 2022Their institution$55,815
ADC Therapeutics America, Inc. · A Phase 1b, Open-Label, Dose-Escalation and Dose-Expansion Study To Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of Camidanlumab Tesirine (Adct-301) As Monotherapy Or in Combination in Patients With Selected Advanced Solid · 2021Their institution$36,300
Seagen Inc. · A Phase 1b Dose Escalation Study of Tucatinib in Combination With Trastuzumab and Oxaliplatin-Based Chemotherapy for Her2+ Gastrointestinal Cancers · 2022Their institution$34,368
Seagen Inc. · A Phase 1b Dose Escalation Study of Tucatinib in Combination With Trastuzumab and Oxaliplatin-Based Chemotherapy for Her2+ Gastrointestinal Cancers · 2021Their institution$16,007
Boehringer Ingelheim Pharmaceuticals, Inc. · Brightline-2: A Phase Iia/Iib, Open-Label, Single-Arm, Multi-Centre Trial of Bi 907828 (Brigimadlin) for Treatment of Patients With Locally Advanced / Metastatic, Mdm2 Amplified, Tp53 Wild-Type Biliary Tract Adenocarcinoma, Pancreatic Ductal Adenocarcinoma, Or Other Selected Solid Tumours · 2025Their institution$14,225
Takeda Pharmaceuticals U.S.A., Inc. · A Phase 1b/2 Study of Tak-981 Plus Pembrolizumab To Evaluate the Safety, Tolerability, and Antitumor Activity of the Combination in Patients With Select Advanced Or Metastatic Solid Tumors · 2025Their institution$7,594
Boehringer Ingelheim Pharma GmbH & Co.KG · Brightline-2 Phiia/Iib Brigimadlin Mono in Mdm2 Amp Tumors · 2024Their institution$2,770
Genentech, Inc. · Ph 1 Ro7568589 in Pancreas Colon and Lung Cancer · 2024Their institution$1,184
Boehringer Ingelheim Pharma GmbH & Co.KG · Brightline 2 Phiia Iib Bi 907828 Mono in Mdm2 Amp · 2023Their institution$698
Takeda Pharmaceuticals U.S.A., Inc. · A Phase 1b/2 Study of Tak-981 Plus Pembrolizumab To Evaluate the Safety, Tolerability, and Antitumor Activity of the Combination in Patients With Select Advanced Or Metastatic Solid Tumors · 2023Their institution$483
Boehringer Ingelheim International GmbH · Brightline 2 Phiia Iib Bi 907828 Mono in Mdm2 Amp · 2023Their institution$299

Professional record

NPI
1467865527
Licence
CA A169072, MA L-260076California A169072: Current · expires 2028-06-30
Trained
Washington University School of Medicine, 2014
Video visits
Lists video visits
Gender
Male
More record details
Sole proprietor
No
Taxonomy
Medical oncology (207RX0202X); Internal medicine (207R00000X); Federal specialty code 207RH0000X (207RH0000X)
Mailing address
300 Pasteur Dr, Stanford, CA, 94305
NPI first listed
2014-06-06
NPI last updated
2024-04-17
NPI record certified
2024-04-17

This is when the NPI record was last certified, not a medical board exam.

Extra NPI addresses: Massachusetts General Hospital, Boston, MA, 02114